Share price · RYTM
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when RYTM's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 17 Nov 2026+8.5%
- 4 Nov 2026+28.0%
- 3 Nov 2026-7.5%
- 29 May 2026-5.0%
- 11 May 2026-7.2%
Nothing announced by RYTM that day or the session before.
- 5 May 2026+7.9%
- 11 Dec 2025+12.3%
Share of unusual movement by asset
For each asset, the share of RYTM's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(3 total)
| Target & Modality | |||
|---|---|---|---|
setmelanotide(Imcivree) | Approved | MC4RPeptide | ObesityBardet-Biedl SyndromeHypothalamic ObesityPrader-Willi Syndrome |
| Phase 2 | MC4RSmall molecule | Hypothalamic Obesity | |
| Phase 1/2 | MC4RPeptide | Obesity |
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (2)
March 2027 (1)
What to watch
2028 (1)
April 2028 (1)
What to watch
Regulatory and conference events
(5)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $92M | $52M | $40M+ $281M short-term inv. | $41M-$3.1M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $71M | $43M | $66M+ $265M short-term inv. | $49M-$9.2M operating cash flow | report ↗ |
| 2026-Q1 | — | $42M | $62M+ $278M short-term inv. | $56M-$44M operating cash flow | report ↗ |
| 2025-Q3 | — | $46M | $52M+ $364M short-term inv. | $53M-$27M operating cash flow | report ↗ |
| 2025-Q2 | — | $42M | $136M+ $155M short-term inv. | $47M-$23M operating cash flow | report ↗ |
| 2025-Q1 | — | $37M | $106M+ $208M short-term inv. | $50M-$40M operating cash flow | report ↗ |
| 2024-Q3 | — | $38M | $48M+ $251M short-term inv. | $44M-$25M operating cash flow | report ↗ |
| 2024-Q2 | $29M | $30M | $162M+ $157M short-term inv. | $32M-$29M operating cash flow | report ↗ |
| 2024-Q1 | $26M | $129M | $53M+ $148M short-term inv. | $141M-$41M operating cash flow | report ↗ |
| 2023-Q3 | $23M | $34M | $65M+ $235M short-term inv. | $44M-$29M operating cash flow | report ↗ |
| 2023-Q2 | $19M | $34M | $116M+ $138M short-term inv. | $47M-$41M operating cash flow | report ↗ |
| 2023-Q1 | $11M | $38M | $110M+ $185M short-term inv. | $52M-$36M operating cash flow | report ↗ |
| 2022-Q3 | $4.3M | $21M | $185M+ $163M short-term inv. | $41M-$47M operating cash flow | report ↗ |
| 2022-Q2 | $9.1M | $31M | $113M+ $122M short-term inv. | $45M-$39M operating cash flow | report ↗ |
| 2022-Q1 | $1.5M | $33M | $79M+ $162M short-term inv. | $53M-$54M operating cash flow | report ↗ |
| 2021-Q3 | $1.0M | $28M | $92M+ $236M short-term inv. | $35M-$40M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $167M | $54M+ $335M short-term inv. | $49M-$116M operating cash flow | report ↗ |
Rhythm Pharmaceuticals reported fourth-quarter IMCIVREE net product revenue of $57.3M and full-year 2025 net product revenue of $194.8M, versus $41.8M and $130.1M, respectively, in 2024. R&D expense was $167.34M, down 29.7% YoY, and the company ended 2025 with cash and equivalents of $54.3M, or approximately $388.9M including short-term investments. Full-year net loss was $196.54M; the fourth-quarter net loss attributable to common stockholders was $48.8M, or $(0.73) per basic and diluted share.
Rhythm guided to 2026 non-GAAP operating expenses of approximately $385M to $415M and expects its current cash position to fund planned operations for at least 24 months. Key clinical updates include the March 20, 2026 PDUFA goal date for setmelanotide in acquired hypothalamic obesity, a positive end-of-Phase-2 FDA meeting for bivamelagon with persistent BMI reductions at six and nine months, and expected March 2026 topline data from the Japanese cohort of the setmelanotide Phase 3 trial in acquired hypothalamic obesity and the Phase 3 EMANATE trial. The company also reported positive preliminary results from its exploratory Phase 2 trial of setmelanotide in Prader-Willi syndrome.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | — | $238M | $89M+ $231M short-term inv. | $65M-$114M operating cash flow | report ↗ |
| 2023-FY | $77M | $135M | $60M+ $216M short-term inv. | $46M-$136M operating cash flow | report ↗ |
| 2022-FY | $24M | $109M | $128M+ $206M short-term inv. | $45M-$173M operating cash flow | report ↗ |
| 2021-FY | $3.1M | $104M | $59M+ $236M short-term inv. | $17M-$146M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 50 sales ($37.1M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-17 | JEAN CHRISTOPHE · director | Option exercise | 10,000 | $34.89 | $349K | Form 4 |
| 2026-11-17 | JEAN CHRISTOPHE · director | Open-market sale | 5,000 | $106.81 | $534K | Form 4 |
| 2026-11-17 | JEAN CHRISTOPHE · director | Open-market sale | 2,500 | $110.00 | $275K | Form 4 |
| 2026-11-17 | JEAN CHRISTOPHE · director | Open-market sale | 2,500 | $115.00 | $288K | Form 4 |
| 2026-11-17 | JEAN CHRISTOPHE · director | Option exercise (derivative) | 10,000 | — | — | Form 4 |
| 2026-09-14 | Meeker David P · director, President and CEO | Option exercise | 50,000 | $6.05 | $303K | Form 4 |
| 2026-09-14 | Meeker David P · director, President and CEO | Open-market sale | 6,439 | $101.75 | $655K | Form 4 |
| 2026-09-14 | Meeker David P · director, President and CEO | Open-market sale | 30,746 | $102.35 | $3.1M | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 284 reporting institutions held 73.6M shares ($6.2B, 106.1% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | RA CAPITAL MANAGEMENT, L.P. | 6,666,837 | $579.8M |
| 2 | BlackRock, Inc. | 6,237,151 | $542.4M |
| 3 | BAKER BROS. ADVISORS LP | 5,604,483 | $487.4M |
| 4 | PRIMECAP MANAGEMENT CO/CA/ | 3,417,509 | $297.2M |
| 5 | VANGUARD PORTFOLIO MANAGEMENT LLC | 3,040,718 | $264.5M |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | 2,967,825 | $258.1M |
| 7 | PERCEPTIVE ADVISORS LLC | 2,373,795 | $206.4M |
| 8 | STATE STREET CORP | 2,271,851 | $197.6M |
| 9 | GOLDMAN SACHS GROUP INC | 1,965,432 | $170.9M |
| 10 | WESTFIELD CAPITAL MANAGEMENT CO LP | 1,929,123 | $167.8M |
| 11 | FMR LLC | 1,689,671 | $147.0M |
| 12 | Polar Capital Holdings Plc | 1,615,586 | $140.5M |
| 13 | CITADEL ADVISORS LLC | 1,418,619 | $123.4M |
| 14 | GEODE CAPITAL MANAGEMENT, LLC | 1,416,269 | $123.2M |
| 15 | JPMORGAN CHASE & CO | 1,553,644 | $120.0M |